Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability

Table 1 Patient Characteristics

		Number of Patients
Age	Median	62 years
	Range	28 to 79 years
Gender	Male	22
	Female	7
Cancer Diagnosis	Colorectal Dukes C	13
	Colorectal Metastatic	10
	Head and Neck	4
	Non-Small Cell Lung Cancer	2
Co-morbidities	None	18
	One or more¹	11
Prior chemotherapy	None	22
	One or more regimens²	7
Study Chemotherapy	Oxaliplatin (130 mg/m²) with Capecitabine (1000 to 2000 mg BID po days 1 to 14)	23
	Cisplatin (100 mg/m²)	4
	Carboplatin (AUC 6 mg*min/ml) with Paclitaxel (200 mg/m²)	2

¹hypertension (6 patients), hypercholesterolaemia (3 patients), goitre, rheumatoid arthritis, gout, benign prostatic hypertrophy, impaired glucose tolerance, ischaemic heart disease, polycythaemia rubra vera; renal stones, duodenal ulcer (1 patient each). ² 5-fluorouracil plus folinic acid (4 patients), single agent capecitabine (3 patients), capecitabine plus irinotecan (2 patients).

ISSN: 1471-2407